Neumora Therapeutics, Inc. (NMRA) stock
NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.33−0.03 (-9.47%)
Close on Nov 17, 2026Market cap $62.85MP/E –Yield –
Neumora Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Neumora Therapeutics's free cash flow for the twelve months ending Dec 31, 2023 was -$163.40M. For fiscal 2023 it was -$163.40M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$163.40M | – |
| FY2022 | Dec 31, 2022 | -$115.41M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | -$51.49M | – |
| Q3 FY2023 | Sep 30, 2023 | -$47.81M | – |
| Q2 FY2023 | Jun 30, 2023 | -$31.02M | – |
| Q1 FY2023 | Mar 31, 2023 | -$33.08M | – |
| Q4 FY2022 | Dec 31, 2022 | -$30.39M | – |
See a number that looks wrong?